Context Therapeutics
Context Therapeutics
CNTX
NASDAQ
0.62
USD
-4.62%
About
Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is building an advanced portfolio of clinical-stage T cell engaging bispecific therapeutics, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-95, a potential first-in-class mesothelin x CD3 bispecific antibody.
CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere.
CTIM-76 has the potential for a wide therapeutic window. The Company’s CT-95 is being developed as a therapy for advanced cancers associated with mesothelin (MSLN) expression..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 80.3K |
| Three Month Average Volume | 5.1M |
| High Low | |
| Fifty-Two Week High | 2.75 USD |
| Fifty-Two Week Low | 0.77 USD |
| Fifty-Two Week High Date | 14 Aug 2024 |
| Fifty-Two Week Low Date | 28 Nov 2023 |
| Price and Volume | |
| Current Price | 2.46 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | 1.68% |
| Thirteen Week Relative Price Change | 16.08% |
| Twenty-Six Week Relative Price Change | 94.55% |
| Fifty-Two Week Relative Price Change | 90.60% |
| Year-to-Date Relative Price Change | 83.84% |
| Price Change | |
| One Day Price Change | 0.41% |
| Thirteen Week Price Change | 24.24% |
| Twenty-Six Week Price Change | 113.91% |
| Five Day Price Change | -0.81% |
| Fifty-Two Week Price Change | 138.83% |
| Year-to-Date Price Change | 117.70% |
| Month-to-Date Price Change | 13.89% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.74352 USD |
| Book Value Per Share (Most Recent Quarter) | 1.34809 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.74352 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.34809 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.77836 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.50095 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.06271 USD |
| Normalized (Last Fiscal Year) | -1.50095 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.50095 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.06271 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.50095 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.06271 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.90503 USD |
| Cash Per Share (Most Recent Quarter) | 1.35385 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.50019 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.72163 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.71573 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 86.93% |
| EPS Change (Trailing Twelve Months) | 9.41% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 16 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -101,536,800 |
| Net Debt (Last Fiscal Year) | -14,449,830 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 64 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -21,047,620 |
| Free Cash Flow (Trailing Twelve Months) | -18,404,430 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -88.71% |
| Return on Assets (Trailing Twelve Months) | -28.46% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -102.79% |
| Return on Equity (Trailing Twelve Months) | -29.68% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -102.79% |
| Return on Investment (Trailing Twelve Months) | -29.68% |
| Return on Investment (5 Year) | -99,999.99% |